PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk.

Abstract Up-regulation of metallo-proteinase (MMP) proteins has been shown in various types of solid cancers and the genotype of MMP1 has been associated with the risk of solid cancers. The contribution of MMP1 genotype to lung cancer has been investigated in various countries, though, to our knowledge, not in Taiwan. Therefore, in this study, we focused on the contribution of a polymorphism in the promoter region of MMP1 to lung cancer risk in Taiwan population.
PMID
Related Publications

Matrix Metalloproteinase-1 Genetic Polymorphism in Breast Cancer in Taiwanese.

Association of MMP1 -1607(1G>2G)single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality.

The Contribution of Matrix Metalloproteinase-1 Genotype to Oral Cancer Susceptibility in Taiwan.

The Contribution of Matrix Metalloproteinase-1 Genotypes to Hepatocellular Carcinoma Susceptibility in Taiwan.

Matrix Metalloproteinase-1 Genotype Contributes to the Risk of Non-solid Tumor in Childhood Leukemia.

Authors

Mayor MeshTerms
Keywords

Genotype

MMP1

Taiwan

lung cancer

non-synonymous

polymorphism

Journal Title anticancer research
Publication Year Start




PMID- 29277780
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung 
      Cancer Risk.
PG  - 253-257
AB  - BACKGROUND/AIM: Up-regulation of metallo-proteinase (MMP) proteins has been shown
      in various types of solid cancers and the genotype of MMP1 has been associated
      with the risk of solid cancers. The contribution of MMP1 genotype to lung cancer 
      has been investigated in various countries, though, to our knowledge, not in
      Taiwan. Therefore, in this study, we focused on the contribution of a
      polymorphism in the promoter region of MMP1 to lung cancer risk in Taiwan
      population. PATIENTS AND METHODS: Genomic DNA was isolated from peripheral blood 
      of 358 patients with lung cancer and 716 healthy individuals (non-cancer
      patients). MMP1 rs1799750 polymorphic genotypes of each sample were determined
      using the typical methodology of polymerase chain reaction-restriction fragment
      length polymorphism (PCR-RFLP). RESULTS: The percentages of 2G/2G, 1G/2G, and
      1G/1G for MMP1 -1607 genotypes were 34.4%, 41.3% and 24.3% in the disease group
      and 33.9%, 44.0%, and 22.1% in the control group (p trend=0.6298), respectively. 
      The results of carrier comparisons in dominant and recessive models also support 
      the findings that 1G or 2G appears not to be a determinant allelic biomarker for 
      Taiwan lung cancer. CONCLUSION: The MMP1 -1607 1G allele is a non-significant
      protective biomarker for lung cancer in Taiwan.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Shen, Te-Chun
AU  - Shen TC
AD  - Graduate Institute of Clinical Medical Science, China Medical University,
      Taichung, Taiwan, R.O.C.
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal
      Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
AD  - Terry Fox Cancer Research Laboratory, China Medical University Hospital,
      Taichung, Taiwan, R.O.C.
FAU - Chang, Wen-Shin
AU  - Chang WS
AD  - Terry Fox Cancer Research Laboratory, China Medical University Hospital,
      Taichung, Taiwan, R.O.C.
FAU - Tsai, Chia-Wen
AU  - Tsai CW
AD  - Terry Fox Cancer Research Laboratory, China Medical University Hospital,
      Taichung, Taiwan, R.O.C.
FAU - Chao, Che-Yi
AU  - Chao CY
AD  - Department of Health and Nutrition Biotechnology, Asia University, Taichung,
      Taiwan, R.O.C.
FAU - Lin, Yi-Ting
AU  - Lin YT
AD  - Terry Fox Cancer Research Laboratory, China Medical University Hospital,
      Taichung, Taiwan, R.O.C.
FAU - Hsiao, Chieh-Lun
AU  - Hsiao CL
AD  - Terry Fox Cancer Research Laboratory, China Medical University Hospital,
      Taichung, Taiwan, R.O.C.
FAU - Hsu, Che-Lun
AU  - Hsu CL
AD  - Department of Otolaryngology, China Medical University Hospital, Taichung,
      Taiwan, R.O.C.
FAU - Chen, Wei-Chun
AU  - Chen WC
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal
      Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
FAU - Hsia, Te-Chun
AU  - Hsia TC
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal
      Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
      [email protected] [email protected]
AD  - Terry Fox Cancer Research Laboratory, China Medical University Hospital,
      Taichung, Taiwan, R.O.C.
FAU - Bau, DA-Tian
AU  - Bau DT
AD  - Graduate Institute of Clinical Medical Science, China Medical University,
      Taichung, Taiwan, R.O.C. [email protected] [email protected]
AD  - Terry Fox Cancer Research Laboratory, China Medical University Hospital,
      Taichung, Taiwan, R.O.C.
AD  - Department of Bioinformatics and Medical Engineering, Asia University, Taichung, 
      Taiwan, R.O.C.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - EC 3.4.24.7 (MMP1 protein, human)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
MH  - Aged
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Lung Neoplasms/*genetics
MH  - Male
MH  - Matrix Metalloproteinase 1/*genetics
MH  - Middle Aged
MH  - Promoter Regions, Genetic
MH  - Risk Factors
MH  - Taiwan/epidemiology
OTO - NOTNLM
OT  - *Genotype
OT  - *MMP1
OT  - *Taiwan
OT  - *lung cancer
OT  - *non-synonymous
OT  - *polymorphism
EDAT- 2017/12/27 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2017/10/21 00:00 [revised]
PHST- 2017/10/27 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 38/1/253 [pii]
AID - 10.21873/anticanres.12215 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):253-257. doi: 10.21873/anticanres.12215.